Becker Stephen P, Froehlich Tanya E, Epstein Jeffery N
*Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; †Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH; ‡Division of Developmental and Behavioral Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
J Dev Behav Pediatr. 2016 Jun;37(5):395-404. doi: 10.1097/DBP.0000000000000285.
To examine the effects of stimulant medication on the sleep functioning of children with attention-deficit/hyperactivity disorder (ADHD) and identify predictors of sleep problems as a side effect of taking stimulant medication.
One hundred sixty-three stimulant-naïve children (72% boys) aged 7 to 11 years diagnosed with ADHD (120 with ADHD predominantly inattentive type, 43 with ADHD combined type) participated in a 4-week, randomized, double-blind, placebo-controlled trial of once-daily (long-acting) methylphenidate (MPH). Parents completed weekly side-effect ratings including an item related to sleep problems.
Ten percent of patients had parent-rated sleep problems before the initiation of medication. Rates of parent-rated sleep problems during MPH titration generally increased with increasing MPH dose (placebo: 8%; low dose: 18%; medium dose: 15%; high dose: 25%). Differences emerged between children with (n = 16) or without (n = 147) preexisting sleep problems. Although 23% of children without preexisting sleep problems went on to have sleep problems at the highest MPH dose, only 37.5% of children with preexisting sleep problems still had sleep problems at the highest MPH dose. Lower weight and lower body mass index (BMI) were associated with increased sleep problems during MPH titration.
This study demonstrated a general association between increased MPH dose and increased sleep problems in children with ADHD, particularly for children of lower weight/BMI. However, a substantial proportion of children with preexisting sleep difficulties no longer had sleep problems on the highest MPH dose, which may help explain mixed findings reported to date in studies examining the impact of MPH on sleep functioning in children with ADHD and suggests that MPH dose titration should not be avoided solely on the basis of a child's premorbid sleep problems. Future research is needed to replicate and extend these findings to more specific domains of sleep functioning and to identify differences between children with persistent or improved sleep functioning as a result of MPH use.
研究兴奋剂药物对注意力缺陷多动障碍(ADHD)儿童睡眠功能的影响,并确定作为服用兴奋剂药物副作用的睡眠问题的预测因素。
163名7至11岁未服用过兴奋剂的ADHD儿童(72%为男孩)(120名主要为注意力不集中型ADHD儿童,43名混合型ADHD儿童)参与了一项为期4周的随机、双盲、安慰剂对照试验,每日服用一次(长效)哌甲酯(MPH)。家长每周完成副作用评分,包括一项与睡眠问题相关的项目。
10%的患者在开始用药前有家长评定的睡眠问题。在MPH滴定期间,家长评定的睡眠问题发生率通常随着MPH剂量的增加而增加(安慰剂组:8%;低剂量组:18%;中等剂量组:15%;高剂量组:25%)。有(n = 16)或无(n = 147)既往睡眠问题的儿童之间出现了差异。虽然23%无既往睡眠问题的儿童在最高MPH剂量时出现了睡眠问题,但只有37.5%有既往睡眠问题的儿童在最高MPH剂量时仍有睡眠问题。较低的体重和较低的体重指数(BMI)与MPH滴定期间睡眠问题增加有关。
本研究表明,ADHD儿童中MPH剂量增加与睡眠问题增加之间存在普遍关联,尤其是体重/ BMI较低的儿童。然而,相当一部分有既往睡眠困难的儿童在最高MPH剂量时不再有睡眠问题,这可能有助于解释迄今为止在研究MPH对ADHD儿童睡眠功能影响的研究中报告的混合结果,并表明不应仅基于儿童病前的睡眠问题而避免MPH剂量滴定。需要进一步的研究来重复和扩展这些发现,以涵盖睡眠功能的更具体领域,并确定因使用MPH而睡眠功能持续存在或改善的儿童之间的差异。